JNJ up +0.42% percent Today $JNJ High is at 108.69 and the

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
JNJ up +0.42% percent Today $JNJ High is at 108.69 and the Low 107.61 with current volume of 894,784.

Recent News posted below.

Johnson & Johnson JNJ other info.
http://investorshangout.com/Johnson--Johnson-JNJ-51518/

JNJ Johnson & Johnson Recent Headline News

DexCom Still A Favorite Diabetes Stock
Bill Gunderson - at Seeking Alpha - 2 hrs 17 mins ago
DexCom (NASDAQ: DXCM ) continues to be one of my favorite diabetes stocks. DexCom, founded in 1999 and based right here in my hometown of San Diego, California, is a medical device company that makes continuous glucose monitoring (CGM) systems. ...
JNJ: 108.30 (+0.14), ABT: 43.90 (+0.09), DXCM: 52.34 (-0.39), MDT: 69.54 (+0.59)

Early Glance: Medical Devices companies
AP - Mon Nov 17, 9:29AM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 10 a.m.:
ZMH: 110.73 (+0.61), JNJ: 108.30 (+0.14), MDT: 69.54 (+0.59), BAX: 71.99 (+0.24)

Early Glance: Pharmaceuticals companies
AP - Mon Nov 17, 9:29AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.30 (+0.14), BAX: 71.99 (+0.24), PFE: 30.32 (-0.02), BMY: 58.21 (+0.26)

5 Rocket Stocks to Buy as Earnings Season Ends: Southwest Airlines and More
at The Street - Mon Nov 17, 9:17AM CST
From a momentum standpoint, stocks are well-positioned to keep up their upside action as we head into the final stretch of 2014.
JNJ: 108.30 (+0.14), ORLY: 177.64 (-2.24), ED: 62.52 (+0.49), LUV: 39.45 (+0.50), CRM: 62.82 (-1.09)

Why Top Dividend Stock Johnson & Johnson Could Plunge in 2015
George Budwell, The Motley Fool - Motley Fool - Mon Nov 17, 7:13AM CST
As the healthcare sector rolls through its third-quarter earnings, a bucolic picture is coming into focus. Earnings across the sector are soaring due to new drug launches, a frenzy of acquisitions, and vast reorganizations that have helped to stem...
JNJ: 108.30 (+0.14), GILD: 100.44 (-1.62), ABBV: 65.14 (+1.14), CELG: 104.66 (+0.61)

Forget Marijuana! This Is a Much Smarter Investment
Sean Williams, The Motley Fool - Motley Fool - Sun Nov 16, 11:11AM CST
Source: Flickr user Oswaldo. Although marijuana initiatives didn't log a perfect sweep in this year's midterm elections, the momentum behind the legalization movement remains intact. Two states (Oregon and Alaska), as well as Washington, D.C.,...
JNJ: 108.30 (+0.14), INSY: 38.50 (-0.07), GWPH: 75.31 (-0.32), GSK: 45.93 (+0.19), NVS: 94.54 (+0.59)

Value Investors' Most Loved Stocks In Q3 2014
Trading Mates Stock Advisor - at Seeking Alpha - Sun Nov 16, 8:09AM CST

NOV: 71.80 (+0.46), JNJ: 108.30 (+0.14), IBM: 164.48 (+0.32), WMT: 83.51 (+0.55), BAC: 17.07 (-0.07), BEN: 56.30 (-0.08), ACN: 84.69 (+0.05), SLB: 95.98 (+0.66), ORCL: 41.18 (+0.34)

3 Ways High-Yield Dividend Stocks Can Help You Recreate Warren Buffett's Investing Success
Adam Galas, The Motley Fool - Motley Fool - Sat Nov 15, 6:05PM CST
Many people consider Warren Buffett the greatest investor in history and it's not hard to understand why. According to a 2012 Yale study, Buffett's company, Berkshire Hathaway , had the best risk-adjusted return of any company or mutual fund that...
KMI: 39.99 (+0.62), MMM: 159.04 (+0.19), JNJ: 108.30 (+0.14), LNCO: 20.39 (-0.54), IBM: 164.48 (+0.32), WFC: 53.39 (+0.04), SDRL: 20.86 (+0.08), PG: 87.78 (-0.33), LINE: 22.37 (-0.28), VNR: 23.93 (-0.55), CL: 67.81 (+0.25)

Johnson & Johnson Part VI: 'Magic Pants' And 'Doubling Pennies'
Robert Honeywill - Seeking Alpha - Sat Nov 15, 6:00AM CST
In Part V of this series, I provided 4 scenarios (8 Cases) illustrating the potential financial outcomes for investors in Johnson & Johnson (NYSE: JNJ ) under changing PE ratios, which are a reflection of changing share prices and changing...
JNJ: 108.30 (+0.14)

Retirement Strategy: Annuities Vs. Dividend Growth Investing For A Lifetime Income
Regarded Solutions - at Seeking Alpha - Fri Nov 14, 11:01PM CST

KO: 42.94 (+0.21), T: 35.90 (unch), JNJ: 108.30 (+0.14), GE: 26.65 (+0.19), XOM: 95.04 (-0.05), MCD: 95.84 (-0.37), PG: 87.77 (-0.34), CVX: 115.98 (-0.34), AAPL: 114.00 (-0.18), WAG: 66.24 (-0.69)

Final Glance: Pharmaceuticals companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.30 (+0.14), BAX: 71.99 (+0.24), PFE: 30.32 (-0.02), BMY: 58.21 (+0.26)

Final Glance: Medical Devices companies
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — Shares of some top medical devices companies were mixed at the close of trading:
ZMH: 110.73 (+0.61), JNJ: 108.30 (+0.14), MDT: 69.53 (+0.58), BAX: 71.99 (+0.24)

Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:00PM CST
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 304.67 (-0.76), JNJ: 108.30 (+0.14), GERN: 3.02 (+0.26), AFFX: 9.39 (-0.32)

Halliburton and Geron are big market movers
AP - Fri Nov 14, 3:29PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
SINA: 39.30 (-0.50), AMZN: 321.03 (-6.79), JNJ: 108.30 (+0.14), HTZ: 22.17 (+0.48), GERN: 3.02 (+0.26), HAL: 49.82 (-5.26), JWN: 73.33 (-0.84), NOK: 7.66 (-0.20), BHI: 66.27 (+6.38)

Geron's Short Squeeze Is Here
Vahan Avetisyan - Seeking Alpha - Fri Nov 14, 2:40PM CST
Geron' s 2014 D eal to the Rescue Geron (NASDAQ: GERN ) surprised Thursday after-hours when it announced news that it entered into an exclusive worldwide license and collaboration agreement to develop its blood disorder drug imetelstat with...
JNJ: 108.30 (+0.14), GERN: 3.02 (+0.26)

Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.39 (+0.28), BIIB: 304.67 (-0.76), JNJ: 108.30 (+0.14), ACT: 247.01 (+3.24)

Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline
at The Street - Fri Nov 14, 2:36PM CST
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 39.30 (-0.50), JNJ: 108.30 (+0.14), HTZ: 22.17 (+0.48), VA: 30.98 (+0.98), GERN: 3.02 (+0.26), JWN: 73.33 (-0.84)

Midday Glance: Pharmaceuticals companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are down at 1 p.m.:
JNJ: 108.30 (+0.14), BAX: 71.99 (+0.24), PFE: 30.32 (-0.02), BMY: 58.21 (+0.26)

Midday Glance: Medical Devices companies
AP - Fri Nov 14, 12:17PM CST
NEW YORK (AP) — Shares of some top medical devices companies are mixed at 1 p.m.:
ZMH: 110.73 (+0.61), JNJ: 108.30 (+0.14), MDT: 69.53 (+0.58), BAX: 71.99 (+0.24)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Stellar's New VP Aims to Bridge Space and Tech

Updated Category News Views 69

Ain't every day you see a heavyweight like Rister stepping into a new role, especially when he's packing thirty years of experience in his tool belt. Bradley J. Rister, now the Vice President of Commercial Solutions Sector at Stellar Solutions, isn't just taking over a desk job. Nope, he's got a pivotal role in gearing up the company’s commercial tech for national...

Continue Reading
SOTERIA Launches Cancer Hunt™ for Military Patients

Updated Category News Views 53

Breaking the Barriers for Our Military's Cancer Fight Diving into the world of precision medicine, SOTERIA Precision Medicine Foundation has sparked a revolution with Cancer Hunt™. It's staggering to think about the piles of bureaucracy and insurance red tape that often stand between cancer patients and life-saving care. Especially when those patients are veterans or...

Continue Reading
ACACIA's Big Move with Bel-Mac and Seashore: Will It Pay Off?

Updated Category News Views 47

A New Powerhouse in Roofing Services? Take a seat, folks—we're talking about a regional shakeup in the world of roofing and exterior building. ACACIA Exterior Building Group, based out of Alexandria, Virginia, just tightened its grip on the Mid-Atlantic and Gulf Coast markets by investing in Bel-Mac Roofing and Seashore Construction. This ain't just your run-of-the-mill...

Continue Reading
Why Haunted Attractions Keep Us Coming Back for Fear

Updated Category News Views 70

Welcome to Fear Incarnated Ah, Kansas City. More than just jazz and barbeque. You’ve got these infamous haunted houses that turn every horror flick into a mere Saturday morning cartoon. Enter Edge of Hell and Beast Haunted Attraction. Two horrifying museums of fear that somehow lure us like flies to sugar from miles away. What's the secret sauce? Well, that’s half the...

Continue Reading
Scientology Aids in Huge Meal Effort After Hurricane

Updated Category News Views 30

Weathering the Storm and Feeding the Survivors Alright, so here's the thing—when a hurricane hits, it doesn't just mess up your weekend plans. We're talking about massive upheaval, like making more than 900,000 folks powerless in the Florida Panhandle. No electricity means no cooking, and in comes the disaster crew to save the day. Enter the Churches of Scientology...

Continue Reading
Hershey's Sweet Results: 2026 Earnings Soar

Updated Category News Views 94

Hershey's 2026 Q3 Financial Performance: A Closer Look At the end of September, The Hershey Company (NYSE: HSY) dished out some eye-popping numbers for their third quarter. With a net sales increase of 3.0%, they clocked in at $3,275.5 million. More importantly, earnings per share-diluted shot up by a whopping 111.8%, landing at $2.88. Clearly, Hershey’s strategic moves...

Continue Reading
Shield HealthCare Expands Access for Astiva Members

Updated Category News Views 76

Opening Up New Avenues for Health Care Here's a nugget from the healthcare sector that's worth chewing on. Shield HealthCare has just inked a deal with Astiva Health that opens the floodgates for eligible members in Southern California to access medical supplies through Shield's extensive network. It's a big move that aims to make health management a tad easier for folks...

Continue Reading
Guidewire Celebrates P&C Insurance Innovators

Updated Category News Views 57

P&C Insurance Takes Center Stage If there's one thing that gets the blood pumping at a conference, it's innovation. This year, Guidewire pulled out all the stops at their Connections Conference in Las Vegas, spotlighting customer and partner triumphs in the P&C insurance sector. From Guidewire Innovation Awards to Partner Excellence Awards, the event was an ode to...

Continue Reading
FuelCell Energy Faces Legal Scrutiny After Stock Plunge

Updated Category News Views 20

FuelCell Energy's Troubling Stock Dive FuelCell Energy's recent plummet isn't just a sobering reality for traders—it comes wrapped in controversy. With NASDAQ:FCEL suffering a 15.69% nosedive after revelations from their fiscal third-quarter results, the ticker’s future hangs precariously. Even for those who've braved the market’s caprices, seeing shares drop $2.68...

Continue Reading
Navigating Homeowner Deductibles: Balancing Costs

Updated Category News Views 93

Understanding the Basics: Premiums and Deductibles Picture sorting through bills with a cup of lukewarm coffee, wondering if there’s a smarter way to handle homeowner insurance. Chuck Montgomery cuts through the fluff, talking turkey about balancing insurance dollars. One part of the game is deciding your deductible, the sum you fork over before insurance steps in...

Continue Reading

Top 5 Most Recently Viewed Articles

HOOKIPA Pharma Unveils Promising HB-700 Preclinical Results

Updated Category News Views 188

HOOKIPA Pharma Showcases Key Preclinical Findings for HB-700 HOOKIPA Pharma Inc. (NASDAQ: HOOK), an innovative clinical-stage biopharmaceutical firm, is proud to present its latest preclinical findings regarding the groundbreaking HB-700 program. This initiative seeks to address KRAS mutated cancers, which are notoriously difficult to treat due to their complex...

Continue Reading
Levi Strauss Focuses on Growth with Potential Dockers Sale

Updated Category News Views 85

Levi Strauss on the Move: Navigating New Opportunities Shares of Levi Strauss (NYSE: LEVI) have seen a positive uptick in after-hours trading recently, thanks to insights shared by Chief Financial Officer Harmit Singh. His remarks indicate an active interest in selling the Dockers brand, a move that may signal significant changes for the company. Elevating the Dockers...

Continue Reading
ICG Enterprise Trust Engages in Strategic Share Buyback

Updated Category News Views 158

ICG Enterprise Trust Engages in Strategic Share Buyback ICG Enterprise Trust plc has recently made a noteworthy move by executing a buyback of its own shares. On December 3, 2024, the company acquired 150,000 shares at an average price of 1326 pence each, planning to hold them as treasury shares. This decision aligns with the company's ongoing commitment to enhancing...

Continue Reading
BULGOLD Secures $1 Million through Private Placement Financing

Updated Category News Views 123

Overview of BULGOLD's Recent Financing BULGOLD Inc. (TSXV: ZLTO) has recently finalized a significant financing round, successfully closing a non-brokered private placement. This strategic move has garnered approximately $1,076,720, achieved through the sale of over 21 million common shares priced at $0.05 each. This financing is pivotal for the company as it aims to...

Continue Reading
Invest in the Future: Why MandalaChain's Presale Matters

Updated Category News Views 282

MandalaChain Presale: A New Era in Blockchain Investment In recent months, the crypto landscape has seen several promising projects emerge, but few have captured investor attention like MandalaChain. This innovative blockchain platform has gained a reputation through its presale, which has seen significant interest globally, indicating a strong showing within the...

Continue Reading